When Merck & Co. pulled Vioxx from pharmacy shelves worldwide on 30 September 2004, chief executive Raymond Gilmartin framed it as a responsible company acting on new data; the documented record shows a five-year gap between that posture and what the company’s own clinicians had measured. Vioxx (rofecoxib), a COX-2 selective anti-inflammatory approved by the U.S. Food and Drug Administration on 20 May 1999 and marketed as a gentler painkiller that spared the stomach, was instead associated with one of the largest drug-safety catastrophes in regulatory history. FDA drug-safety reviewer David Graham would testify to the Senate Finance Committee on 18 November 2004 that the drug had caused on the order of 88,000 to 139,000 excess heart attacks and strokes in the United States, of which perhaps 30 to 40 percent were fatal — a toll he compared to between two and four jumbo-jet crashes a week sustained over five years.
The gap between promise and reality was not discovered late; it was visible in Merck’s own trials. The VIGOR study, published in The New England Journal of Medicine on 23 November 2000 under lead author Claire Bombardier, showed that the 8,076 patients taking rofecoxib had roughly four to five times the rate of myocardial infarction of patients taking the older drug naproxen — a relative risk the published paper reported as 0.2 in naproxen’s favor. Merck attributed the difference to a supposed protective effect of naproxen rather than a cardiac hazard of Vioxx — a hypothesis that was never proven and that the company continued to advance while sales climbed past $2.5 billion a year and a sales force of more than 3,000 representatives carried the message to prescribers.
The withdrawal came only when the harm became impossible to explain away. The APPROVe trial — designed to test whether Vioxx prevented recurrent colon polyps, not to study the heart — was halted early on 23 September 2004 after showing that rofecoxib roughly doubled the risk of confirmed cardiovascular events after eighteen months of use, against placebo. The verdict here is therefore plain at the outset: an approved, heavily advertised, trusted medicine reached tens of millions of patients while the signal that would eventually condemn it sat in the company’s data, the FDA’s review files, and the medical literature, fully legible to anyone with access and the will to read it.
What followed was the largest pharmaceutical mass-tort reckoning of its era. In November 2007 Merck agreed to pay $4.85 billion to resolve roughly 27,000 lawsuits covering some 47,000 plaintiff groups, NEJM issued a formal “Expression of Concern” alleging the VIGOR authors had withheld cardiac data, and the case became the standard byword for how surrogate-endpoint approval, aggressive marketing, and suppressed safety signals can converge into mass harm before any regulator pulls the cord.
When Bayer AG voluntarily withdrew Baycol (cerivastatin) from the worldwide market on 8 August 2001, the company described it as a precaution against a rising “reporting rate” of muscle injury; the documented record shows that the latecomer statin had already been associated with fatal rhabdomyolysis at roughly forty to fifty times the rate of its competitors, a hazard that was foreseeable from its known pharmacology and visible in adverse-event data well before the recall. Cerivastatin, the sixth statin to reach the U.S. market and approved by the Food and Drug Administration in June 1997, was promoted as a potent, low-dose entrant in an already crowded class. It captured slightly under 4 percent of the U.S. statin market — and yet, by the FDA’s own count at withdrawal, it accounted for 31 American deaths from rhabdomyolysis, a condition in which skeletal muscle disintegrates, floods the bloodstream with myoglobin, and shuts down the kidneys.
The gap between promise and reality was not a matter of rare bad luck. In an analysis by FDA scientists, the relative reporting rate of fatal rhabdomyolysis was on the order of forty times higher for cerivastatin than for the other approved statins; for all rhabdomyolysis, fatal and nonfatal, the figure was roughly fifty-four times higher. The danger was concentrated and predictable: it rose with the 0.8 mg high dose Bayer had introduced to compete on potency, rose in elderly patients, and rose catastrophically when cerivastatin was combined with gemfibrozil, a fibrate that interfered with the drug’s clearance. Twelve of the 31 U.S. deaths involved that very combination — a combination Bayer had contraindicated on the label, but which physicians prescribed in numbers the warning failed to suppress.
The withdrawal came only when the body count made the signal undeniable. The verdict here is therefore plain at the outset: an approved cholesterol drug holding a minority share of its market produced a disproportionate share of its class’s fatal harm, because a known drug-interaction hazard and an aggressive high-dose strategy were allowed to reach roughly six million patients while the contraindication label substituted for the market action the data warranted.
What followed was a transatlantic litigation reckoning. Bayer faced on the order of 7,800 product-liability suits in the United States alone — a figure that grew past 12,000 — and ultimately paid well over $1 billion to settle claims, while internal documents pried loose in discovery showed company scientists had flagged the gemfibrozil danger and the rising death reports before the recall. Baycol became the standard cautionary case for how a “me-too” drug competing on potency can convert a known interaction into mass casualties.
When the U.S. Food and Drug Administration asked Warner-Lambert to pull Rezulin from the market on 21 March 2000, it ended a three-year arc in which a celebrated first-in-class diabetes pill killed at least 63 people through liver failure while the warning that should have stopped it had been visible from before launch. Rezulin (troglitazone), the first thiazolidinedione — an oral “insulin sensitizer” acting on the PPAR-gamma receptor — was approved on 29 January 1997 and marketed as a breakthrough that let type 2 diabetics use their own insulin more effectively. The gap between that promise and the harm was not subtle: the drug produced idiosyncratic, sometimes fulminant hepatotoxicity, and Britain’s Glaxo Wellcome withdrew it from the U.K. market on 1 December 1997 — barely ten months after the U.S. approval — while the FDA kept it on American shelves for another twenty-eight months.
The signal was institutional, not merely clinical. The FDA medical officer originally assigned to the application, Dr. John Gueriguian, had recommended against approval over cardiac and liver concerns; he was removed from the review on 4 November 1996, and his negative analysis was purged from the official record before the drug was cleared on an expedited timeline. Within the first year of marketing, serious hepatotoxicity reports accumulated, and an internal FDA memorandum cited 135 reports of serious liver injury by late 1997. Public Citizen’s Health Research Group, led by Dr. Sidney Wolfe, petitioned for withdrawal in July 1998, asking the agency how many more Americans would have to die or need transplants.
The verdict is therefore plain at the outset: a profitable, regulator-blessed, heavily prescribed medicine reached nearly two million Americans while the evidence that condemned it — a foreign withdrawal, a buried internal review, mounting death reports, and an outside petition — sat fully legible in the record. The FDA’s response was incrementalism: four label changes between 1997 and 1999 adding ever-stricter liver-monitoring instructions that real-world prescribing could not reliably execute, rather than removal.
What finally forced the withdrawal was arithmetic the labels could not fix. Once two safer thiazolidinediones — rosiglitazone and pioglitazone — reached the market in 1999 without the same fatal liver signal, Rezulin’s risk-benefit case collapsed, and the FDA requested its removal on 21 March 2000. Litigation followed: Warner-Lambert, absorbed by Pfizer in 2000, ultimately resolved roughly 35,000 claims for an estimated $750 million, and “Rezulin” became a byword for how a buried safety review and an ignored foreign recall can keep a lethal drug on the market for years.
When Janssen Pharmaceutica — the Belgian unit of Johnson & Johnson — announced on 23 March 2000 that it would stop general U.S. marketing of Propulsid, it presented the move as a precaution; the documented record shows a drug the company’s own labels had flagged as potentially lethal since 1995, kept on the open market for five more years while prescriptions ran past thirty million. Propulsid (cisapride) was a gastrointestinal prokinetic approved by the U.S. Food and Drug Administration in 1993 for nighttime heartburn from gastroesophageal reflux. It worked by speeding the gut, but it also blocked a cardiac potassium channel, prolonging the QT interval and, in vulnerable patients, triggering torsades de pointes — a chaotic ventricular arrhythmia that can stop the heart.
The gap between the indication and the harm was the whole tragedy. Cisapride was approved for adult reflux, but its danger concentrated in people who should never have received it: patients taking common interacting drugs — the macrolide antibiotics erythromycin and clarithromycin, the antifungals ketoconazole, itraconazole and fluconazole — that raised cisapride’s blood levels, and patients with underlying cardiac or metabolic risk. By the FDA’s accounting, of the 341 serious arrhythmias and 80 deaths reported through December 1999, roughly 85 percent occurred in patients with a recognized contraindication or risk factor. The drug was, in effect, safe in the population that did not need protecting and dangerous in the population that did.
The verdict is therefore plain at the outset: an approved, widely prescribed heartburn pill killed through interactions its manufacturer and the FDA had named in the label years before the withdrawal, and a meaningful share of the dead were infants and children who received it off-label for colic and reflux even though it was never approved for pediatric use. One observational study of roughly 58,000 premature infants found that about a fifth had been given cisapride.
What followed was a slow regulatory unwind and a mass-tort settlement. Janssen halted general sale effective 14 July 2000, retaining only a tightly controlled limited-access protocol; in 2004 Johnson & Johnson agreed to pay up to $90 million to resolve claims that the drug caused some 300 deaths and nearly 16,000 injuries. Propulsid became the textbook case of a “Dear Doctor” letter and a black box that did not change prescribing fast enough to stop the dying.
When Pfizer pulled Bextra from the U.S. market on 7 April 2005 — not voluntarily, but at the written request of the U.S. Food and Drug Administration — the company described a balanced judgment about risks and benefits; the documented record shows a drug whose dangers had been measurable for at least a year and whose marketing had outrun every safety signal it generated. Bextra (valdecoxib), a COX-2 selective anti-inflammatory developed by G. D. Searle/Pharmacia and co-promoted by Pfizer after approval on 20 November 2001 for osteoarthritis, rheumatoid arthritis, and menstrual pain, was withdrawn for two converging harms: an excess of heart attacks and strokes, and a rare but lethal class of skin reactions. The FDA concluded the drug offered no demonstrated advantage over existing NSAIDs to justify either.
The cardiovascular signal was not theoretical. A randomized trial in 1,671 cardiac-surgery patients — Nussmeier et al., published in The New England Journal of Medicine on 17 March 2005 — found that patients given parecoxib followed by valdecoxib after coronary-artery-bypass-graft surgery suffered cardiovascular events at a risk ratio of 3.7 (95% confidence interval 1.0–13.5; P=0.03), roughly 2.0 percent versus 0.5 percent on placebo. This was the same COX-2 hazard that had condemned Vioxx six months earlier, surfacing in Pfizer’s own franchise.
The dermatologic harm was, if anything, more distinctive. Because valdecoxib is a sulfonamide, it carried a strong association with Stevens-Johnson syndrome and toxic epidermal necrolysis — conditions in which the skin blisters and sloughs and which kill a meaningful fraction of those who develop them. By the end of March 2004 the FDA had logged on the order of 63 reported cases of SJS/TEN tied to the drug, several of them fatal. In mid-October 2004, Pfizer sent physicians a warning letter; a boxed warning followed; the withdrawal followed that. The verdict is therefore plain at the outset: a me-too painkiller with no proven edge over cheap generics was kept on the market and aggressively promoted while it accumulated both a cardiac body count and a roster of fatal skin reactions — and the reckoning, when it came, took the form of the largest health-care fraud prosecution the Justice Department had ever brought.
When Abbott Laboratories agreed on 8 October 2010 to pull Meridia (sibutramine) from the U.S. market at the request of the Food and Drug Administration, the company maintained that the drug remained safe for its approved population; the documented record shows that the very trial regulators had ordered Abbott to run had measured the opposite, and had measured it in the patients most likely to receive a weight-loss prescription. Sibutramine, a serotonin–norepinephrine reuptake inhibitor approved by the FDA in November 1997 as an appetite suppressant for obese patients, was instead found to raise the risk of nonfatal heart attack and stroke by roughly 16 percent while delivering a placebo-adjusted weight loss of only about 2.5 percent of body weight after five years.
The gap between promise and harm was not a late surprise; it was the product of a contradiction visible at approval. Sibutramine worked by raising levels of norepinephrine and serotonin to blunt appetite, and that same sympathetic activation predictably raised blood pressure and heart rate. A drug marketed to obese patients — a group already loaded with cardiovascular risk — carried a mechanism that pushed the cardiovascular system in exactly the wrong direction. The FDA approved it anyway on a surrogate endpoint, pounds lost on a scale, and deferred the question of whether those pounds came at the cost of hearts.
The answer arrived in the Sibutramine Cardiovascular Outcomes Trial, or SCOUT, a roughly 10,744-patient study that European regulators had demanded as a post-marketing condition. After a mean of 3.4 years of follow-up, the primary composite outcome — nonfatal myocardial infarction, nonfatal stroke, resuscitated cardiac arrest, and cardiovascular death — occurred in 11.4 percent of the sibutramine group versus 10.0 percent of placebo (hazard ratio 1.16; p=0.015). The verdict is therefore plain at the outset: a drug whose central trade-off was legible from its pharmacology in 1997 was permitted to circulate for thirteen years until the safety trial its makers were compelled to conduct confirmed the harm.
What followed was a coordinated transatlantic revocation rather than a courtroom reckoning. The European Medicines Agency suspended sibutramine on 21 January 2010; the FDA recommended against its use and accepted Abbott’s voluntary withdrawal that October. Sibutramine became the byword for a specific failure mode in obesity medicine: approving a drug on a weight surrogate when its own mechanism telegraphs a cardiovascular hazard, then waiting a decade-plus for a mandated outcomes trial to state the obvious.
When the U.S. Food and Drug Administration announced on 29 March 2007 that the makers of pergolide had agreed to pull the drug from the American market, the action was filed as a routine post-market safety measure; the documented record shows that the fibrotic heart-valve mechanism that condemned Permax had been understood, in chemical detail, for years before the echocardiograms were read. Pergolide (marketed by Eli Lilly as Permax and approved by the FDA in 1988 as an adjunct to levodopa for Parkinson’s disease) was an ergot-derived dopamine agonist that relieved tremor and rigidity by stimulating dopamine receptors — but it also bound potently to the 5-HT2B serotonin receptor on heart-valve tissue, the identical target that had driven the valvulopathy behind the 1997 fen-phen catastrophe.
The gap between promise and harm was not an unforeseeable side effect. Two studies published side by side in The New England Journal of Medicine on 4 January 2007 closed the case. René Schade and colleagues, mining the U.K. General Practice Research Database cohort of 11,417 patients, found that pergolide carried an adjusted incidence-rate ratio of 7.1 (95% CI 2.3-22.3) for newly diagnosed cardiac-valve regurgitation. Renzo Zanettini’s echocardiographic study found clinically important (moderate-to-severe) regurgitation in 23.4 percent of pergolide patients versus 5.6 percent of controls — and, decisively, 0 percent in patients on non-ergot dopamine agonists, which do not hit the 5-HT2B receptor.
The verdict is therefore plain at the outset: a drug with no proven efficacy advantage over safer, mechanistically distinct alternatives kept hundreds of thousands of Parkinson’s patients exposed to a known fibrotic hazard years after the signal was legible. The FDA asked Lilly to add valvulopathy to the warnings section in 2003 and mandated a boxed warning in 2006; neither step removed the drug. Only the 2007 NEJM pair forced a withdrawal the pharmacology had argued for since at least 2002 — a quieter case than the blockbuster scandals, with no settlement fund and no Senate hearing, only a back-of-the-shelf agent kept in front-line use long after a receptor profile shared with a recalled diet drug had told clinicians exactly where to look.